Middle East and Africa pharma economy to reach US$38.8 billion by 2021
CPHI Middle East & Africa opens in Abu Dhabi as finished dosage formulations expand quickly, driven by government reforms to further increase local manufacturing.
CPHI MEA (Middle East and Africa) launches next month as favourable market conditions are driving increased growth across the Middle East and North Africa (MENA) pharma market – ageing and gentrifying populations, increased healthcare spending, and a modernising supply chain are transforming prospects in the region.
Total pharma sales have reached an impressive $32 billion across MENA as a whole – the Middle East accounts for $20.3 billion and North Africa $10.7 billion. The increasingly gentrified populations in Sub-Saharan African countries and the development of sophisticated universal healthcare systems in the Middle East are providing robust growth opportunities.
In particular, the finished dosage formulation sector is expanding particularly quickly in the Middle East, with a number of plants being commissioned in the last few years. In the UAE, the government also fast-tracks approval of locally manufactured drugs, which is helping to establish a new manufacturing base in the country – with the added potential for exports to the Gulf Cooperation Council.
Commenting on the region’s generic sector Cara Turner, Brand Director – CPHI Middle East & Africa, UBM, added, “Many companies are receiving a direct boost from government policy changes and are building new manufacturing facilities in the region, which is seeing the sector perform strongly. Domestic production accounts for approximately 45% of drug consumption in the Middle East, with generics in the GCC alone valued at $1.55 billion in 2016.”
Saudi Arabia remains the biggest pharma market in the region according to 2017 sales numbers at $7.5bn, with Turkey ($6.9bn), Egypt ($3.4bn) and the UAE ($3.17bn) following closely behind. However, overall the North Africa region is predicted to see the fastest growth rates in the next few years at 7.6% CAGR.
“The Middle East and Africa market is evolving at a rapid pace, and opportunities are plentiful for regional and international pharma companies. However, it can be a difficult region to navigate due to the lack of an overall governing body. Internationals looking to access the market need an appreciation of differing rules, regulation and systems in operation. It’s one of the reasons we are launching CPHI MEA this year as we believe we can help accelerate domestic international growth. Increasingly, we are seeing a number of affluent and high growth pharma companies emerge – which presents ample opportunity to form international partnerships.” added Turner.
CPHI Middle East & Africa – organised by UBM (part of Informa Plc) – will launch at the ADNEC centre, Abu Dhabi for the first time this year on 3-5 September 2018. In a region that relies heavily on imported ingredients and the maintenance of a reliable network of distributors, CPHI MEA is specifically tailored to facilitate new connections between regional and multinational businesses and optimize existing partnerships.
The event will attract key decision makers and budget holders from the region to meet with 4000+ attendees – 50% of which are from outside the MEA region – and 250 local, regional and international exhibitors. In fact, such has been the demand in the last few months that the organisers have had to add a further 348 square metres (7%) of floor space.
The exhibition will also feature co-located events, Finished-Dosage-Formulation (FDF), ICSE, P-MEC and InnoPack providing a comprehensive overview of all steps of the supply chain in one location. Representatives from APIs, excipients, IT, analytical services, contract manufacturing, clinical trials, packaging, machinery, and more will be present.
Jerome Carle, General Manager at Julphar says of the event, "The MEA plays a more and more important role in the global pharmaceutical market. This event will give exposure to regional players, stimulate discussion on key regional and international issues and create meaningful opportunities for collaboration. It will also provide a unique opportunity to gain insights into the latest trends and developments that are shaping the landscape of the industry. For companies that do not have a footprint in the MEA, this will also be a great opportunity to find strong partners to help them navigate in the region and build their strategies."
Related News
-
News Closing 2024 with Editors' picks of top articles from the past year
Coming to the end of 2024 and it’s certainly been a busy year, for CPHI and for the rest of the pharmaceutical and healthcare industry. Topics of conversation throughout the last 12 months have been varied, touching on the technical, to the polit... -
News SCHOTT Pharma’s sustainable journey with CPHI
Sustainability is of paramount importance in the pharmaceutical industry. See how a recent partnership between CPHI and SCHOTT Pharma has helped to highlight and accelerate their sustainability journey to reach global goals. -
News CPHI Podcast Series: Investing in a vision for the future of life sciences
In this episode Lucy Chard is joined by Rajiv Khatau to discuss the importance of looking into new therapeutic areas and some of the more niche areas of pharmaceuticals, and investing in the future of the industry. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News CPHI Milan 2024: Excerpts from the Exhibitors
After another successful year of bringing the pharmaceutical community together at CPHI Milan in October, hear direct from the exhibitors on why the event is so important for them and the industry as a whole. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo... -
News Key Insights from the Heart of Pharma: an exclusive CPHI Online report
CPHI Milan, held from October 8–10, 2024 in the historic Fiera Milano, celebrated its 35th edition of bringing together the pharmaceutical industry and supply chain for 3 days of collaborating and innovating. Our first CPHI Wrap-Up Report brings ...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance